BBA
IMVT icon

Baker Bros. Advisors’s Immunovant IMVT Stock Holding History

Baker Bros. Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$136M Hold
5,457,881
– – 0.78% 18
2025
Q4 		$139M Hold
5,457,881
– – 0.81% 18
2025
Q3 		$88M Hold
5,457,881
– – 0.64% 20
2025
Q2 		$87.3M Hold
5,457,881
– – 0.85% 15
2025
Q1 		$93.3M Buy
5,457,881
+3,750,000
+220% +$78.4M 1.03% 14
2024
Q4 		$42.3M Buy
1,707,881
+482,471
+39% +$13.7M 0.45% 29
2024
Q3 		$34.9M Buy
1,225,410
+760,692
+164% +$22.4M 0.36% 30
2024
Q2 		$12.3M Buy
464,718
+39,709
+9% +$1.13M 0.16% 45
2024
Q1 		$13.7M Hold
425,009
– – 0.17% 42
2023
Q4 		$17.9M Hold
425,009
– – 0.2% 39
2023
Q3 		$16.3M Buy
+425,009
New +$9.61M 0.09% 40

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Baker Bros. Advisors's IMVT Position: Q1 2026 in Review

Baker Bros. Advisors held its Immunovant (IMVT) position steady in Q1 2026 at 5,457,881 shares worth $136M. The position accounts for 0.78% of the portfolio, ranked #18.

Baker Bros. Advisors first reported a position in IMVT in Q3 2023 and has held it in 11 quarters since. The position peaked at $139M in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Baker Bros. Advisors held 5,457,881 shares of Immunovant worth $136M as of Q1 2026.
  • Baker Bros. Advisors left its Immunovant share count unchanged in Q1 2026.
  • Immunovant made up 0.78% of Baker Bros. Advisors's portfolio in Q1 2026, its #18 holding.
  • Baker Bros. Advisors first reported a position in Immunovant in Q3 2023 and has held it in 11 quarters since.
  • Baker Bros. Advisors's Immunovant position peaked at $139M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.